Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to SunMed, and Alston & Bird is serving as legal counsel to Avanos. SunMed announced it has entered into...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised GreenLight Biosciences, Foley Hoag advised the Special Committee, while O’Melveny & Myers advised Fall Line on the deal. GreenLight Biosciences Holdings, PBC (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Morgan Lewis represented Merck in the transaction. Merck closed its exclusive license and collaboration agreement with Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd., to...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
You must be a Standard 1 Year member to access this content.
